Antileukotriene agents for the treatment of lung disease (Q28293842)

https://api.crossref.org/works/10.1164%2FRCCM.201301-0023PP

The leukotriene E4 puzzle: finding the missing pieces and revealing the pathobiologic implications

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.201301-0023PP

Effects of montelukast and budesonide on airway responses and airway inflammation in asthma

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.201301-0023PP

The leukotriene receptor antagonist zafirlukast inhibits sulfur dioxide-induced bronchoconstriction in patients with asthma

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.201301-0023PP

Correlation between cysteinyl leukotriene release from leukocytes and clinical response to a leukotriene inhibitor

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.201301-0023PP

Zileuton, a leukotriene synthesis inhibitor in the management of chronic asthma. Clinical pharmacokinetics and safety

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.201301-0023PP

Effects of montelukast and beclomethasone on airway function and asthma control

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.201301-0023PP

Effects of 6 weeks of therapy with oral doses of ICI 204,219, a leukotriene D4 receptor antagonist, in subjects with bronchial asthma. ACCOLATE Asthma Trialists Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.201301-0023PP

Improvements in distal lung function correlate with asthma symptoms after treatment with oral montelukast.

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.201301-0023PP

Oral montelukast, inhaled beclomethasone, and placebo for chronic asthma. A randomized, controlled trial. Montelukast/Beclomethasone Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.201301-0023PP

Urinary leukotriene E4/exhaled nitric oxide ratio and montelukast response in childhood asthma

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.201301-0023PP

Improvement of aspirin-intolerant asthma by montelukast, a leukotriene antagonist: a randomized, double-blind, placebo-controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.201301-0023PP

A randomized, comparative, multicentric clinical trial to assess the efficacy and safety of zileuton extended-release tablets with montelukast sodium tablets in patients suffering from chronic persistent asthma

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.201301-0023PP

Leukotriene antagonists as first-line or add-on asthma-controller therapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.201301-0023PP

Montelukast improves asthma control in asthmatic children maintained on inhaled corticosteroids

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.201301-0023PP

Distribution of therapeutic response in asthma control between oral montelukast and inhaled beclomethasone

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.201301-0023PP

Randomised controlled trial of montelukast plus inhaled budesonide versus double dose inhaled budesonide in adult patients with asthma

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.201301-0023PP

Addition of leukotriene antagonists to therapy in chronic persistent asthma: a randomised double-blind placebo-controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.201301-0023PP

Randomised, placebo controlled trial of effect of a leukotriene receptor antagonist, montelukast, on tapering inhaled corticosteroids in asthmatic patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.201301-0023PP

Montelukast and fluticasone compared with salmeterol and fluticasone in protecting against asthma exacerbation in adults: one year, double blind, randomised, comparative trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.201301-0023PP

Comparison of inhaled salmeterol and oral zafirlukast in patients with asthma

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.201301-0023PP

Addition of montelukast or salmeterol to fluticasone for protection against asthma attacks: a randomized, double-blind, multicenter study

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.201301-0023PP

Montelukast once daily inhibits exercise-induced bronchoconstriction in 6- to 14-year-old children with asthma

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.201301-0023PP

The national montelukast survey

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.201301-0023PP

The role of inhaled corticosteroids and montelukast in children with mild-moderate asthma: results of a systematic review with meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.201301-0023PP

Effect of inhaled glucocorticoids in childhood on adult height

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.201301-0023PP

Step-up therapy for children with uncontrolled asthma receiving inhaled corticosteroids

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.201301-0023PP

Elevations of local leukotriene C4 levelsduring viral upper respiratory tract infections

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.201301-0023PP

A randomized trial of montelukast in respiratory syncytial virus postbronchiolitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.201301-0023PP

A randomized intervention of montelukast for post-bronchiolitis: effect on eosinophil degranulation

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.201301-0023PP

A double-blind, placebo-controlled, randomized trial of montelukast for acute bronchiolitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.201301-0023PP

Study of montelukast for the treatment of respiratory symptoms of post-respiratory syncytial virus bronchiolitis in children

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.201301-0023PP

Montelukast does not prevent reactive airway disease in young children hospitalized for RSV bronchiolitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.201301-0023PP

Montelukast reduces asthma exacerbations in 2- to 5-year-old children with intermittent asthma

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.201301-0023PP

Leukotriene-receptor expression on nasal mucosal inflammatory cells in aspirin-sensitive rhinosinusitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.201301-0023PP

Influence of body mass index on the response to asthma controller agents

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.201301-0023PP

Smoking affects response to inhaled corticosteroids or leukotriene receptor antagonists in asthma

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.201301-0023PP

Exposure to tobacco smoke increases leukotriene E4-related albuterol usage and response to montelukast.

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.201301-0023PP

Montelukast for treating seasonal allergic rhinitis: a randomized, double-blind, placebo-controlled trial performed in the spring

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.201301-0023PP

A randomized controlled trial of intravenous montelukast in acute asthma

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.201301-0023PP

A randomized placebo-controlled study of intravenous montelukast for the treatment of acute asthma

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.201301-0023PP

A randomized, double-blind, placebo-controlled trial of oral montelukast in acute asthma exacerbation

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.201301-0023PP

Cost effectiveness of leukotriene modifiers in adults with asthma

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.201301-0023PP

Cost-effectiveness comparison of salmeterol/fluticasone propionate versus montelukast in the treatment of adults with persistent asthma

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.201301-0023PP

Cost-efficacy analysis of fluticasone propionate versus zafirlukast in patients with persistent asthma

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.201301-0023PP

Reports of suicidality in clinical trials of montelukast

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.201301-0023PP

Risk of suicide attempt in asthmatic children and young adults prescribed leukotriene-modifying agents: a nested case-control study

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.201301-0023PP

Churg-Strauss syndrome in two patients receiving montelukast

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.201301-0023PP

The relationship of asthma therapy and Churg-Strauss syndrome: NIH workshop summary report

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.201301-0023PP

CysLT2 receptors interact with CysLT1 receptors and down-modulate cysteinyl leukotriene dependent mitogenic responses of mast cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.201301-0023PP

Constitutive activation of 5-lipoxygenase in the lungs of patients with idiopathic pulmonary fibrosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.201301-0023PP

Increased alveolar nitric oxide concentration and high levels of leukotriene B(4) and 8-isoprostane in exhaled breath condensate in patients with asbestosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.201301-0023PP

Protection from pulmonary fibrosis in leukotriene-deficient mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.201301-0023PP

Muscarinic receptors, leukotriene B4 production and neutrophilic inflammation in COPD patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.201301-0023PP

Cysteinyl leukotriene 1 receptor expression associated with bronchial inflammation in severe exacerbations of COPD

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.201301-0023PP

Short-term effects of montelukast in stable patients with moderate to severe COPD.

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.201301-0023PP

Randomized trial of zileuton for treatment of COPD exacerbations requiring hospitalization

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.201301-0023PP

Increased urinary leukotriene E4 excretion in obstructive sleep apnea: effects of obesity and hypoxia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.201301-0023PP

Cysteinyl leukotriene receptors in tonsillar B- and T-lymphocytes from children with obstructive sleep apnea.

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.201301-0023PP

Montelukast for children with obstructive sleep apnea: a double-blind, placebo-controlled study

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.201301-0023PP

21 January 2018

Eicosanoids and cancer

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.201301-0023PP

Inhibition of 5-lipoxygenase-activating protein (FLAP) reduces pulmonary vascular reactivity and pulmonary hypertension in hypoxic rats

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.201301-0023PP

Leukotrienes: underappreciated mediators of innate immune responses

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.201301-0023PP

Leukotriene B4 amplifies NF-κB activation in mouse macrophages by reducing SOCS1 inhibition of MyD88 expression

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.201301-0023PP

Association between leukotriene receptor antagonist therapy and Churg-Strauss syndrome: an analysis of the FDA AERS database

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.201301-0023PP